The Central Nervous System Treatment Market is expanding due to the rising prevalence of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, stroke, epilepsy, and mood disorders. Increasing life expectancy and growing awareness about early diagnosis are accelerating demand for advanced therapeutics. Innovations in biologics, targeted drug delivery systems, and immunomodulatory therapies are also contributing to improved treatment outcomes. Furthermore, pharmaceutical companies are investing heavily in research and development to address unmet clinical needs in neurodegenerative and mental health disorders.

What Is the Central Nervous System Treatment Market Size and Forecast?

The global Central Nervous System Treatment Market size was valued at USD 128.56 Billion in 2025 and is projected to grow at a CAGR of 6.10%, reaching USD 232.41 Billion by 2035. This steady growth reflects increasing healthcare expenditure, expanding patient populations, and rapid adoption of innovative biologics and non-biologic drugs across major healthcare systems.

Central Nervous System Treatment Market Share by Disease Type and Drug Class

The Central Nervous System Treatment Market share is segmented by disease type into neurovascular diseases, neurodegenerative diseases, mental health disorders, and infectious diseases. Neurodegenerative diseases such as Alzheimer’s and Parkinson’s account for a significant share due to their high global burden. Mental health conditions, including epilepsy, mood disorders, and anxiety disorders, are also major contributors.

By drug class, the market includes immunomodulatory drugs, interferons, dopamine agonists, antidepressants, analgesics, and decarboxylase inhibitors. Biologics are gaining strong traction due to their targeted mechanism of action, while non-biologics continue to dominate in terms of prescription volume.

Request sample report Explore

Central Nervous System Treatment Market Trends and Regional Insights

Key Central Nervous System Treatment Market trends include the development of precision medicine, increased use of combination therapies, and digital health integration for neurological monitoring. North America holds the leading regional position due to advanced healthcare infrastructure and high R&D spending, followed by Europe and Asia Pacific. Emerging markets in Latin America and the Middle East and Africa are experiencing gradual growth due to improving access to neurological care.